Skip to content
Psilocybin Technology
Menu
  • Home
  • Contact us about Psilocybin Science and Technology

Category: State of the Art

Business / Law / Patents / Research / State of the Art

Psychedelic Patents – The Cat’s Out of the Bag

Patents on Psychedelics are No Longer a Novel Idea In January of 2020, we published an article about “Psychedelic Investment Opportunities,” in which reiterated our earlier position (from 2019) that …

Business / Molecules vs. Mushrooms / Mushrooms / Psilocybin / Psilocybin Chemistry / Psilocybin Derivatives / Psilocybin Science / State of the Art

Psychedelic Investment Opportunities – 2020 Perspective

Investing in psychedelics (e.g., magic mushrooms, psilocybin, etc.) has became a hot topic during 2019.  Following Peter Thiel’s investment in Compass Pathway in 2018, several high-profile investors entered the psychedelic …

Psilocybin Chemistry / Psilocybin Science / State of the Art / Unmet Need

American Chemical Society Meeting – Only One Talk about Psychedelics?

The upcoming 2019 American Chemical Society (“ACS”) Fall Meeting and Exposition in San Diego features two presentations pertaining to psychedelic chemistry: (1) a talk by Dr. David Manke and Dr. …

Microdosing / Molecules vs. Mushrooms / Mushrooms / State of the Art / Treatment / Unmet Need

Review of the State of the Art for Microdosing Psychedelics

As of July 2019 the state of the art for microdosing psychedelics is best described as a collection anecdotal reports from people taking unknown amounts of unknown drugs at wildly …

Business / Molecules vs. Mushrooms / Mushrooms / Psilocybin Chemistry / State of the Art / Wood Lover Paralysis

Why Formulations are Better than Mushrooms

Formulations made from magic mushrooms offer some advantages over mushroom fruiting bodies or natural preparations.  We previously discussed the analogy between cannabis and magic mushrooms.  Both cannabis and magic mushrooms …

Business / Psilocybin / Research / State of the Art

Compass Pathways’s Patents

In late April of 2019, both the United States Patent and Trademark Office (“USPTO”) and the World Intellectual Property Office (“WIPO”) published Compass Pathways’s Patent Applications directed to psilocybin technology.  …

Business / Mushrooms / Psilocybin / Research / State of the Art

Investing in Psychedelics, Psilocybin, or Magic Mushrooms

** See also recent article on “Investing in Psychedelics – a 2020 Perspective” ** [Updated December 2019] Are magic mushrooms (or psilocybin) going to be the next big investment opportunity …

Business / State of the Art

Rolling Stone: The Future of Cannabis is Formulations of Cannabinoids

Madison Margolin recently published an article in Rolling Stone Magazine explaining that the future of cannabis technology will center around formulated products that eliminate the inherent variability of natural cannabis.  …

Business / Depression / Molecules vs. Mushrooms / Mushrooms / Psilocybin / Research / State of the Art

No Magic Mushroom Monopoly

No Magic Mushroom Monopoly Relax. No one is trying to monopolize magic mushrooms.  COMPASS Pathways is not trying to monopolize magic mushrooms.  Renewed interest in psychedelic medicine (e.g., psilocybin) is not part …

Business / Psilocin / Psilocybin / Psilocybin Chemistry / Psilocybin Derivatives / State of the Art

Cost of Psilocybin

Cost of Psilocybin How much should psilocybin cost — per gram and per dose? With the renewed interest in psilocybin, some have questioned whether commercial involvement will impede access to …

Posts navigation

Older posts

Recent Posts

  • Nova Mentis Launches Entourage Effect Research
  • Graham Pechenik and Noah Potter discuss Psychedelic Patents
  • MindMed – Two Steps Closer to Next Generation Magic Mushroom Formulations
  • COMPASS Pathways’ $100+ Million Crystalline Form Patent
  • MagicMed – The First Psychedelic Patent Troll?

Recent Comments

  • Psilocybin Expert on Taking Pure Psilocybin is Different from Eating Magic Mushrooms
  • jim on Cannabis and Magic Mushrooms – A Near Perfect Analogy
  • jeff on China Enters Magic Mushroom Industry – Wuhan, MJMedTech, and M2BIO
  • jeff on Chemical & Engineering News Discusses Entourage Effect
  • jeff on Psilocybin Clinical Trials Approved by FDA

Archives

  • January 2021
  • November 2020
  • September 2020
  • July 2020
  • February 2020
  • January 2020
  • December 2019
  • August 2019
  • July 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • November 2017
  • October 2017

Categories

  • Aeruginascin
  • Anxiety
  • Business
  • Cognitive Enhancement
  • Decriminalization
  • Depression
  • Law
  • Legalization
  • Mass
  • Microdosing
  • Molecules vs. Mushrooms
  • Mushrooms
  • Patents
  • Psilocin
  • Psilocybin
  • Psilocybin Chemistry
  • Psilocybin Derivatives
  • Psilocybin Science
  • Research
  • State of the Art
  • Treatment
  • Uncategorized
  • Unmet Need
  • Wood Lover Paralysis

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
Copyright © 2021 Psilocybin Technology – OnePress theme by FameThemes